论文部分内容阅读
目的研究吡喃阿霉素治疗淋巴瘤的疗效。方法选取长葛市人民医院于2013年8月至2015年2月接收入院的淋巴瘤患者84例,利用随机分表法将84例患者均分成研究组与对照组。研究组行吡喃阿霉素治疗,对照组行阿霉素治疗。分析并对比两组的临床用药效果。结果研究组治疗的总有效率为78.57%,对照组为66.67%。研究组的疗效显著优于对照组。两组对比,差异有统计学意义(P<0.05)。研究组用药后出现不良反应19例,占45.24%;对照组出现不良反应32例,占76.19%。研究组不良反应的发生率(45.24%)显著低于对照组(76.19%)。两组对比,差异有统计学意义(P<0.05)。结论吡喃阿霉素作为淋巴瘤患者的首选治疗药物不仅能提升疗效,还能减少患者不良反应的发生,既安全,又可靠。
Objective To study the efficacy of pirarubicin in the treatment of lymphoma. Methods Eighty-four patients with lymphoma admitted to Changge People’s Hospital from August 2013 to February 2015 were enrolled. All 84 patients were divided into study group and control group by random sub-table method. The study group was treated with pirarubicin and the control group with doxorubicin. Analyze and compare the clinical efficacy of the two groups. Results The total effective rate of the study group was 78.57% and that of the control group was 66.67%. The study group was significantly better than the control group. The difference between the two groups was statistically significant (P <0.05). There were 19 adverse reactions (45.24%) in the study group and 32 (76.19%) adverse reactions in the control group. The incidence of adverse reactions in the study group (45.24%) was significantly lower than that in the control group (76.19%). The difference between the two groups was statistically significant (P <0.05). Conclusion Pirarubicin is the first choice of treatment for patients with lymphoma, which not only can improve the curative effect, but also reduce the occurrence of adverse reactions in patients. It is safe and reliable.